Business Insider

NewLink Genetics Outlines 2018 Business Priorities to Support Phase 3 Pivotal Trial of Indoximod Plus PD-1 InhibitorsNewLink Genetics updates financial and clinical guidance

AMES, Iowa, Jan. 08, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced Indigo301, the name of its upcoming Phase 3 trial of indoximod plus PD-1 inhibitors for ...
Nature

Outline of a medical genetics curriculum for internal medicine residency training programs

To keep pace with the rapid advances in medical genetics, internal medicine residency training programs need to train internists to develop new attitudes, knowledge bases, and skill sets. Currently, ...
Seeking Alpha

Myriad Genetics outlines high single-digit to low double-digit growth target through cancer care continuum focus

Leffler announced, "We are raising our full year revenue range to $818 million to $828 million, largely reflecting our positive Q2 revenue performance." Gross margin guidance increased to between 69.5 ...
Reuters

Newlink Genetics Outlines 2018 Business Priorities

* NEWLINK GENETICS CORP - PHASE 2 RESULTS FOR INDOXIMOD + PD-1 BLOCKADE IN ADVANCED MELANOMA EXPECTED IN 2018 * NEWLINK GENETICS CORP - PHASE 2 RESULTS FOR INDOXIMOD + GEM/NAB-PACLITAXEL IN PANCREATIC ...
The Dispatch / The Rock Island Argus

Genetics company outlines request for state aid

DES MOINES, Iowa (AP) -- Trans Ova Genetics has presented legislative leaders with a detailed proposal for spending $33 million it wants the state to invest in a proposed biodefense facility and other ...